Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
Portfolio Pulse from
Anixa Biosciences has completed dosing in the third cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer, in collaboration with Moffitt Cancer Center.
February 26, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences has completed dosing in the third cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer, in collaboration with Moffitt Cancer Center.
The completion of dosing in the third cohort of a Phase 1 trial is a significant milestone in drug development, indicating progress and potential efficacy of the therapy. This news is likely to positively impact Anixa's stock price as it demonstrates advancement in their cancer treatment pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100